UCB researchers like Jessica Williamson, PhD, come to work driven by a singular purpose – to create value for people living with severe disease. That’s because patients depend on the important work of scientific research to discover new medical innovations that will help them achieve their goals. Read more from Dr. Williamson about why she's passionate about innovating for patients and UCB's growing research presence in the greater Boston area.

At UCB, we keep patients at the center - inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. We have a rich heritage in epilepsy, and today, we’re shining a spotlight on seizure clusters, which can affect people with uncontrolled epilepsy, to help spread awareness. Check out the full infographic below.

At UCB, we keep patients at the center - inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. We have a rich heritage in epilepsy, and today, we’re shining a spotlight on seizure clusters, which can affect people with uncontrolled epilepsy, to help spread awareness.

• The Phase 3 BE VIVID study evaluating the efficacy and safety of bimekizumab in adults with moderate-to-severe chronic plaque psoriasis met all primary and ranked secondary endpointsⁱ

Learn more about living with non-radiographic axial spondyloarthritis (nr-axSpA) from Chelsea, who recently shared her story.

• Will enhance UCB’s leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB’s rozanolixizumab, an FcRn targeting antibody also in phase 3

At UCB, we keep patients at the center of everything we do, inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. Read more from UCB's CEO and Chairman of the Executive Committee, Jean-Christophe Tellier, about why it's time to come together across all healthcare stakeholders to deliver more for patients.

UCB Global Regulatory Affairs Fellows (L to R): Howraa Alasker, PharmD and Tanya Chaudhri, PharmD, RPh

The 2020-2022 UCB Global Regulatory Affairs (GRA) PharmD Fellowship Program, a collaboration with the Industry Pharmacists Organization (IPhO), is a 2-year rotational program located at UCB’s Atlanta campus aimed at growing top regulatory talent for the future. Established in 2017, the Fellowship Program is designed to provide PharmD graduates with the opportunity to learn and experience all aspects of regulatory affairs under the mentorship of experienced preceptors. Applications are being accepted now until November 1, 2019. Learn more about the fellowship from current fellow, Tanya Chaudhri, PharmD, RPh.